-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Tops Q4 EPS by 3c
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $30 at RBC Capital
-
-
-
-
-
-
-
Ocular Therapeutix completes enrollment in wet AMD drug trial
-
-
-
-
-
-
-
Chardan Capital Markets Starts Ocular Therapeutix (OCUL) at Buy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) announce inducement grants to new employee
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDR
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

